Telix Pharmaceuticals (TLX) Operating Leases (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Operating Leases for 3 consecutive years, with $62.1 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 1066.11% to $62.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.1 million through Dec 2025, up 1066.11% year-over-year, with the annual reading at $62.1 million for FY2025, 842.35% up from the prior year.
  • Operating Leases for Q4 2025 was $62.1 million at Telix Pharmaceuticals, up from $5.3 million in the prior quarter.
  • The five-year high for Operating Leases was $62.1 million in Q4 2025, with the low at $5.0 million in Q4 2023.
  • Average Operating Leases over 3 years is $24.1 million, with a median of $5.3 million recorded in 2024.
  • The sharpest move saw Operating Leases grew 6.53% in 2024, then soared 1066.11% in 2025.
  • Over 3 years, Operating Leases stood at $5.0 million in 2023, then grew by 6.53% to $5.3 million in 2024, then skyrocketed by 1066.11% to $62.1 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $62.1 million, $5.3 million, and $5.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.